Psoriasis Treatment Options: Biologics, Topicals, Light Therapy, and Functional Approaches

How Psoriasis Treatment Is Categorized

Psoriasis treatment follows a severity-based framework. Body surface area (BSA), Psoriasis Area and Severity Index (PASI), and quality-of-life impact determine where you start [1]. But severity is not the only factor. Location matters: genital, facial, scalp, and nail psoriasis can justify systemic therapy even when BSA is low because of disproportionate functional and psychological impact.

The treatment landscape has changed dramatically in the past decade. Biologics that target specific immune pathways now achieve clearance rates that would have been unthinkable with older systemic agents. The question is no longer whether psoriasis can be controlled but which approach fits your disease profile, lifestyle, and risk tolerance.

Topical Treatments

Corticosteroids

The workhorse of mild psoriasis. Available in potencies from mild (hydrocortisone 1%) to super-potent (clobetasol propionate 0.05%). Vehicle matters: ointments are most potent, followed by creams, lotions, foams, and solutions [2].

Best practices:

• Use mid-to-high potency for body plaques, low potency for face and skin folds
• Apply once or twice daily during flares for 2-4 weeks
• Taper to intermittent maintenance (2-3x/week) to prevent rebound
• Avoid continuous high-potency use beyond 4 weeks to reduce atrophy risk

Expected outcome: 50-70% of mild psoriasis patients achieve adequate control with topicals alone.

Vitamin D Analogs (Calcipotriol, Calcitriol)

Slow keratinocyte proliferation and promote normal differentiation. Less effective than potent corticosteroids as monotherapy but valuable as combination partners. The calcipotriol/betamethasone combination (Enstilar, Taclonex) is one of the best-performing topical combinations in clinical trials [3].

Topical Retinoids (Tazarotene)

Normalizes keratinocyte differentiation. Can cause significant irritation, so it is often combined with a corticosteroid. Works well for nail and palmoplantar psoriasis. Apply every other night initially to build tolerance.

Calcineurin Inhibitors (Tacrolimus, Pimecrolimus)

Off-label for psoriasis but useful for facial and intertriginous (skin fold) psoriasis where steroid atrophy is a concern. They lack the efficacy for thick plaques but are safe for long-term use in sensitive areas.

Tapinarof (Vtama)

A newer topical aryl hydrocarbon receptor agonist approved in 2022 for plaque psoriasis. It offers a steroid-free option with no atrophy risk. PASI 75 rates of approximately 36-40% at 12 weeks in trials [4]. Useful for patients seeking to avoid steroids long-term.

Roflumilast Cream (Zoryve)

A topical PDE4 inhibitor approved in 2022. Effective for intertriginous psoriasis specifically. Lower efficacy than potent steroids for thick plaques but a good option for sensitive areas.

Phototherapy

Narrowband UVB (NB-UVB)

The standard phototherapy for psoriasis. Treatments 2-3 times weekly for 8-12 weeks in a light booth. Clearance rates of 60-80% are typical with consistent attendance [5].

Advantages: no systemic immunosuppression, safe in pregnancy, effective across all body areas. Disadvantages: requires frequent clinic visits (though home units are available by prescription), sunburn risk, long-term photodamage and theoretical skin cancer risk with cumulative exposure.

Excimer Laser (308 nm)

Targeted UVB delivery to individual plaques. Ideal for localized disease (fewer than 10% BSA). Higher doses can be delivered to plaques without exposing unaffected skin. Effective for stubborn plaques that resist topicals.

PUVA (Psoralen + UVA)

Once the gold standard, now used less frequently due to the increased skin cancer risk with cumulative treatments. Still useful for thick palmoplantar psoriasis and when NB-UVB fails. Limited to 150-200 lifetime treatments.

Traditional Systemic Agents

Methotrexate

The oldest systemic psoriasis therapy still in common use. Given weekly (oral or subcutaneous), it suppresses T-cell activation and keratinocyte proliferation. PASI 75 rates of 35-40% at 16 weeks [6].

Monitoring requirements: CBC, liver enzymes, and renal function every 8-12 weeks. Folate supplementation (1 mg daily or 5 mg the day after methotrexate) reduces side effects. Liver biopsy or FibroScan is recommended after cumulative dose of 3.5-4 g or if LFTs are persistently elevated.

Main advantages: inexpensive ($5-20/month generic), effective for psoriatic arthritis, long safety track record. Main disadvantages: hepatotoxicity risk, teratogenicity, fatigue, nausea, lower efficacy than biologics.

Cyclosporine

A calcineurin inhibitor that provides rapid disease control. PASI 75 in 50-70% of patients at 12-16 weeks. Limited to short courses (3-6 months maximum, ideally) due to nephrotoxicity and hypertension risk [7].

Best used as a “bridge” therapy: rapid disease control while transitioning to a biologic or other maintenance agent. Also useful for acute flares and erythrodermic psoriasis.

Acitretin

An oral retinoid. Modestly effective as monotherapy (PASI 75 in 25-30%) but highly effective combined with phototherapy. The combination of acitretin + NB-UVB is synergistic and allows lower UV doses.

Important: acitretin is teratogenic and has a 3-year washout period in women of childbearing potential (it converts to etretinate, which is stored in fat tissue). This makes it primarily used in postmenopausal women and men.

Apremilast (Otezla)

An oral PDE4 inhibitor. PASI 75 rates of 28-33% at 16 weeks, lower than biologics but with a more favorable safety profile and no immunosuppression monitoring [8]. Common side effects include nausea, diarrhea, headache, and weight loss (5 kg average in clinical trials).

Best suited for moderate psoriasis patients who prefer an oral medication and are not candidates for or decline biologics. Also approved for psoriatic arthritis.

Deucravacitinib (Sotyktu)

A selective TYK2 inhibitor approved in 2022. Oral, once-daily dosing. PASI 75 rates of 53-58% at 16 weeks, significantly outperforming apremilast in the head-to-head POETYK PSO-3 trial. No requirement for routine lab monitoring. Represents a new class of targeted oral systemic therapy that narrows the efficacy gap with biologics.

Biologic Therapies

Biologics target specific immune mediators driving psoriasis. They are the most effective treatments available and have transformed outcomes for moderate-to-severe disease.

TNF Inhibitors

The first-generation biologics for psoriasis.

• Adalimumab (Humira/biosimilars): PASI 75 in 60-70%. Now available as less expensive biosimilars. Subcutaneous injection every 2 weeks.
• Etanercept (Enbrel): PASI 75 in 45-55%. Oldest TNF inhibitor still used. Twice weekly initially, then weekly.
• Infliximab (Remicade): PASI 75 in 75-80%. IV infusion at 0, 2, and 6 weeks, then every 8 weeks. Most potent TNF inhibitor but requires infusion center visits.
• Certolizumab pegol (Cimzia): PASI 75 in 65-75%. Does not cross the placenta, making it the preferred biologic during pregnancy.

IL-17 Inhibitors

Higher efficacy than TNF inhibitors for skin psoriasis.

• Secukinumab (Cosentyx): PASI 90 in 54-60%. Monthly subcutaneous injection after loading.
• Ixekizumab (Taltz): PASI 90 in 65-71%. Biweekly loading, then monthly. Among the fastest-acting biologics.
• Brodalumab (Siliq): PASI 100 (complete clearance) in 37-44%. Unique mechanism: blocks IL-17 receptor rather than the cytokine itself. Carries a boxed warning for suicidal ideation, though the causal relationship is debated [9].
• Bimekizumab (Bimzelx): Dual IL-17A and IL-17F inhibitor. PASI 90 in 67-75% at 16 weeks. The most potent IL-17 agent available. Higher rate of oral candidiasis than single IL-17 inhibitors.

IL-23 Inhibitors

Target the upstream driver of the Th17 pathway. Fewer injections and durable responses.

• Guselkumab (Tremfya): PASI 90 in 70-73%. Every 8 weeks after loading. Excellent durability of response.
• Risankizumab (Skyrizi): PASI 90 in 72-75%. Every 12 weeks after loading. PASI 100 in 40-50%. Among the highest clearance rates of any biologic [10].
• Tildrakizumab (Ilumya): PASI 90 in 35-45%. Less potent than guselkumab and risankizumab but good safety profile. Every 12 weeks.

IL-12/23 Inhibitor

• Ustekinumab (Stelara): PASI 75 in 67-76%. Every 12 weeks after loading. Weight-based dosing. Long safety record (10+ years). Now outperformed by newer agents in head-to-head trials but still widely used. Biosimilars becoming available.

Choosing Between Treatments

The treatment decision should account for disease severity, location, comorbidities, patient preference, cost, and insurance coverage. A simplified decision framework:

Functional and Integrative Approaches

Alongside conventional treatment, these interventions have supporting evidence:

• Stress reduction: Mindfulness-based stress reduction (MBSR) has been studied as a psoriasis adjunct. A small RCT showed faster clearance during phototherapy in the MBSR group.
• Gut health optimization: Psoriasis patients show gut microbiome dysbiosis. Addressing gut health through diet, probiotics, and eliminating food sensitivities may reduce systemic inflammation.
• Vitamin D optimization: Maintaining serum 25-OH vitamin D at 40-60 ng/mL. Deficiency is common in psoriasis and normalizing levels may reduce flare frequency.
• Exercise: Regular moderate exercise reduces systemic inflammatory markers. 150 minutes/week of moderate activity is associated with improved psoriasis outcomes.

Related Reading

• Psoriasis: The Evidence-Based Guide (Pillar)
• Scalp Psoriasis: Causes, Treatments, and What Actually Clears It
• Psoriasis Diet: Foods That Help, Foods That Trigger Flares

References

1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j.jaad.2018.11.057
2. Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi:10.1155/2012/561018
3. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product. Br J Dermatol. 2006;154(6):1155-1160. doi:10.1111/j.1365-2133.2006.07231.x
4. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-2229. doi:10.1056/NEJMoa2103629
5. Almutawa F, Alnomair N, Wang Y, et al. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol. 2013;14(2):87-109. doi:10.1007/s40257-013-0015-y
6. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP). Lancet. 2017;389(10068):528-537. doi:10.1016/S0140-6736(16)32127-4
7. Griffiths CEM, Katsambas A, Dijkmans BAC, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155(Suppl 2):1-16. doi:10.1111/j.1365-2133.2006.07558.x
8. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026. doi:10.1136/annrheumdis-2013-205056
9. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824
10. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2). Lancet. 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6